Zenas BioPharma, Inc. 8K

Zenas BioPharma’s 8-K discloses Q2 2026 results, FDA acceptance of its obexelimab BLA with a May 27, 2027 PDUFA date, key pipeline and governance updates, and a CFO transition to a strategic advisory role with interim finance leadership assigned to the President and COO.

Zenas BioPharma, Inc. reported its second quarter 2026 financial results and issued a broad corporate update, highlighted by the U.S. FDA’s August acceptance of its Biologics License Application for obexelimab for IgG4-related disease with a PDUFA target action date of May 27, 2027, ongoing and upcoming clinical milestones across obexelimab, ZB021, and orelabrutinib, and multiple regulatory and partnering activities. The company also announced new bioequivalence data for an obexelimab autoinjector pen, continued progress in Phase 2 and Phase 3 trials in systemic lupus erythematosus and multiple sclerosis, and early-stage pipeline advancement for ZB022 and ZB014. Governance and leadership actions included the appointment of industry veteran Christy Oliger to the Board of Directors and the planned transition of CFO and Chief Business Officer Jennifer Fox to a Strategic Advisor role effective September 30, 2026, with President and COO Joe Farmer assuming Principal Financial Officer and Principal Accounting Officer responsibilities on an interim basis. Financially, Zenas reported a net loss of $111.5 million for the quarter on higher R&D, G&A, and acquired in-process R&D expenses, cash, cash equivalents and investments of $673.9 million as of June 30, 2026, and guided that its liquidity, supplemented by potential milestone and debt facility draws tied to FDA approval of obexelimab, is expected to fund operations at least through the second quarter of 2029.

Filing Facts

CIK

1953926

Ticker

ZBIO

Form

8K

Source Type

fda

Accession

0001104659-26-095437

Alert Tier

7